Nasdaq

Design Therapeutics Announces Update on DT-168 Program for Fuchs Endothelial Corneal Dystrophy at Eyecelerator 2025

Design Therapeutics is set to present significant safety findings from its Phase 1 trial of DT-168, highlighting progress in their clinical development for treating Fuchs endothelial corneal dystrophy ...
News Medical

Study uncovers mechanisms behind Fuchs Endothelial Corneal Dystrophy

Important insights into the mechanisms behind Fuchs Endothelial Corneal Dystrophy (FECD), a common cause of age-related visual loss, have been revealed in a new study led by UCL researchers. The study ...
Medicine Buffalo

NIH Renews Parker’s Funding to Study Corneal Diseases

The National Institutes of Health has renewed its funding of eye disease research led by Mark D. Parker, PhD, associate professor of physiology and biophysics. The National Eye Institute is funding a ...
Morningstar

Design Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal Dystrophy

CARLSBAD, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, ...
Seeking Alpha

Design Therapeutics, Inc. (DSGN) Presents at Cantor Global Healthcare Conference 2025 Transcript

All right. We're ready to get started. Welcome, everyone. I'm Josh Schimmer from the Cantor Biotech Equity Research team. I'm pleased to introduce from Design Therapeutics, we have Pratik Shah, Chief ...